| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Skye Bioscience Inc (OTCQB: SKYE)
SKYE Technical Analysis
2
| As on 24th Dec 2024 SKYE STOCK Price closed @ 2.61 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.64 & Buy for SHORT-TERM with Stoploss of 0.83 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SKYESTOCK Price
| Open | 2.55 | Change | Price | % |
| High | 2.63 | 1 Day | 0.10 | 3.98 |
| Low | 2.48 | 1 Week | -0.64 | -19.69 |
| Close | 2.61 | 1 Month | -2.83 | -52.02 |
| Volume | 56746 | 1 Year | 2.59 | 12950.00 |
| 52 Week High 18.00 | 52 Week Low 0.01 | ||||
OTCQB USA Most Active Stocks
| FNMAS | 10.12 | 2.33% |
| FMCKJ | 9.73 | 0.83% |
| BMIX | 0.01 | % |
| BTCWF | 0.10 | 150.00% |
| ALPP | 3.56 | 0.00% |
| ALPP | 3.56 | 0.00% |
| NWBO | 0.31 | -3.12% |
| VKIN | 0.23 | 0.00% |
| FNMA | 2.65 | 0.76% |
| LTSRF | 0.15 | -6.25% |
OTCQB USA Top Gainers Stocks
OTCQB USA Top Losers Stocks
| SKYE Daily Charts |
SKYE Intraday Charts |
Whats New @ Bazaartrend |
SKYE Free Analysis |
|
|
SKYE Important Levels Intraday
| RESISTANCE | 2.90 |
| RESISTANCE | 2.81 |
| RESISTANCE | 2.75 |
| RESISTANCE | 2.69 |
| SUPPORT | 2.53 |
| SUPPORT | 2.47 |
| SUPPORT | 2.41 |
| SUPPORT | 2.32 |
SKYE Forecast December 2024
| 4th UP Forecast | 21.86 |
| 3rd UP Forecast | 15.69 |
| 2nd UP Forecast | 11.87 |
| 1st UP Forecast | 8.05 |
| 1st DOWN Forecast | -2.83 |
| 2nd DOWN Forecast | -6.65 |
| 3rd DOWN Forecast | -10.47 |
| 4th DOWN Forecast | -16.64 |
SKYE Weekly Forecast
| 4th UP Forecast | 2.63 |
| 3rd UP Forecast | 2.62 |
| 2nd UP Forecast | 2.62 |
| 1st UP Forecast | 2.62 |
| 1st DOWN Forecast | 2.60 |
| 2nd DOWN Forecast | 2.60 |
| 3rd DOWN Forecast | 2.60 |
| 4th DOWN Forecast | 2.59 |
SKYE Forecast2024
| 4th UP Forecast | 39.99 |
| 3rd UP Forecast | 28 |
| 2nd UP Forecast | 20.59 |
| 1st UP Forecast | 13.18 |
| 1st DOWN Forecast | -7.96 |
| 2nd DOWN Forecast | -15.37 |
| 3rd DOWN Forecast | -22.78 |
| 4th DOWN Forecast | -34.77 |
Skye Bioscience Inc ( OTCQB USA Symbol : SKYE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SKYE Business Profile
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based therapeutics for the treatment of infectious diseases. The company's lead product candidate is THCVHS, which is in preclinical trials for the treatment of glaucoma. It is also developing CBDVHS that is in preclinical trials to treat various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and Cannabinoid Cocktail for the treatment of anti-infective diseases. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California. Address: 5910 Pacific Center Boulevard, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service